Premium
Brexit and the EMA: what's next for the UK?
Author(s) -
Buckland Danny
Publication year - 2017
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.1575
Subject(s) - brexit , medicine , negotiation , agency (philosophy) , international trade , european union , law , political science , economics , sociology , social science
When Theresa May triggered Article 50 on 29 March, the UK began a two‐year process of negotiations to exit the EU, which is likely to include a divorce from the European Medicines Agency (EMA). But what will fill the gap left by the EMA and what will be the impact on new drugs coming to the market?